QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
Log in
NASDAQ:SAVA

Cassava Sciences Stock Forecast, Price & News

$50.06
+1.48 (+3.05 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$49.52
Now: $50.06
$53.50
50-Day Range
$8.18
MA: $34.77
$87.95
52-Week Range
$1.63
Now: $50.06
$117.54
Volume2.54 million shs
Average Volume10.05 million shs
Market Capitalization$1.28 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
Cassava Sciences logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SAVA
CUSIPN/A
CIKN/A
Phone512-501-2444
Employees9
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.01 per share

Profitability

Net Income$-4,630,000.00

Miscellaneous

Market Cap$1.28 billion
Next Earnings Date3/25/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.93 out of 5 stars

Medical Sector

1059th out of 1,966 stocks

Pharmaceutical Preparations Industry

489th out of 772 stocks

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$50.06
+1.48 (+3.05 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SAVA News and Ratings via Email

Sign-up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cassava Sciences (NASDAQ:SAVA) Frequently Asked Questions

Is Cassava Sciences a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cassava Sciences stock.
View analyst ratings for Cassava Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Cassava Sciences?

Wall Street analysts have given Cassava Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cassava Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cassava Sciences?

Cassava Sciences saw a decline in short interest during the month of February. As of February 12th, there was short interest totaling 2,620,000 shares, a decline of 56.2% from the January 28th total of 5,980,000 shares. Based on an average daily trading volume, of 6,640,000 shares, the short-interest ratio is currently 0.4 days.
View Cassava Sciences' Short Interest
.

When is Cassava Sciences' next earnings date?

Cassava Sciences is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021.
View our earnings forecast for Cassava Sciences
.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) announced its quarterly earnings data on Monday, November, 9th. The company reported ($0.06) EPS for the quarter, topping the Zacks' consensus estimate of ($0.07) by $0.01.
View Cassava Sciences' earnings history
.

How has Cassava Sciences' stock price been impacted by COVID-19 (Coronavirus)?

Cassava Sciences' stock was trading at $4.24 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SAVA stock has increased by 1,080.7% and is now trading at $50.06.
View which stocks have been most impacted by COVID-19
.

When did Cassava Sciences' stock split? How did Cassava Sciences' stock split work?

Shares of Cassava Sciences reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SAVA?

3 Wall Street analysts have issued 12-month target prices for Cassava Sciences' shares. Their forecasts range from $14.00 to $24.00. On average, they expect Cassava Sciences' stock price to reach $19.33 in the next year. This suggests that the stock has a possible downside of 61.4%.
View analysts' price targets for Cassava Sciences
or view top-rated stocks among Wall Street analysts.

Who are Cassava Sciences' key executives?

Cassava Sciences' management team includes the following people:
  • Mr. Remi Barbier, Founder, Chairman, Pres & CEO (Age 61, Pay $906.37k)
  • Mr. Eric J. Schoen, Chief Financial Officer (Age 53, Pay $251.37k)
  • Dr. Nadav Friedmann, Chief Medical & Operating Officer and Director (Age 78, Pay $333.54k)
  • Dr. George Thornton, Sr. VP of Technology
  • Mr. Michael Zamloot, Sr. VP of Technical Operations
  • Dr. Michael Marsman, Sr. VP of Regulatory Affairs
  • Dr. Lindsay H. Burns Ph.D., Sr. VP of Neuroscience
  • Dr. James W. Kupiec M.D., Chief Clinical Devel. Officer

Who are some of Cassava Sciences' key competitors?

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

What is Cassava Sciences' stock symbol?

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.70%), Caas Capital Management LP (2.69%), Nuveen Asset Management LLC (2.39%), Northern Trust Corp (1.36%), Bleichroeder LP (1.11%) and CM Management LLC (0.68%). Company insiders that own Cassava Sciences stock include Eric Schoen, Remi Barbier and Sanford Robertson.
View institutional ownership trends for Cassava Sciences
.

Which institutional investors are selling Cassava Sciences stock?

SAVA stock was sold by a variety of institutional investors in the last quarter, including Bleichroeder LP, ExodusPoint Capital Management LP, Alliancebernstein L.P., and Creative Planning.
View insider buying and selling activity for Cassava Sciences
or view top insider-selling stocks.

Which institutional investors are buying Cassava Sciences stock?

SAVA stock was acquired by a variety of institutional investors in the last quarter, including Caas Capital Management LP, BlackRock Inc., Nuveen Asset Management LLC, CM Management LLC, Wells Fargo & Company MN, Squarepoint Ops LLC, Northern Trust Corp, and Investors Financial Group LLC. Company insiders that have bought Cassava Sciences stock in the last two years include Eric Schoen, Remi Barbier, and Sanford Robertson.
View insider buying and selling activity for Cassava Sciences
or or view top insider-buying stocks.

How do I buy shares of Cassava Sciences?

Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cassava Sciences' stock price today?

One share of SAVA stock can currently be purchased for approximately $50.06.

How much money does Cassava Sciences make?

Cassava Sciences has a market capitalization of $1.28 billion. The company earns $-4,630,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does Cassava Sciences have?

Cassava Sciences employs 9 workers across the globe.

What is Cassava Sciences' official website?

The official website for Cassava Sciences is www.cassavasciences.com.

Where are Cassava Sciences' headquarters?

Cassava Sciences is headquartered at 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731.

How can I contact Cassava Sciences?

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at 512-501-2444 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.